CTMX CytomX Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-87.7%
TTM net income YoY-404.9%
TTM EPS YoY-329.6%
Revenue 3-yr CAGR-43.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-676.5%
Net margin-609.0%
FCF margin-363.6%
EBITDA margin—
Returns
ROE-43.6%
ROA-32.7%
ROIC (approx.)-46.3%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets21.9%
Debt / equity0.00x
Current ratio7.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M |
| R&D expense | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M |
| SG&A expense | $29.84M | $29.73M | $30.02M | $42.85M | $39.16M |
| Operating income | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M |
| Pretax income | -$17.13M | $32.09M | $3.32M | -$99.32M | -$115.87M |
| Income tax | $238,000 | $224,000 | $3.89M | $0 | $0 |
| Net income | -$17.37M | $31.87M | -$569,000 | -$99.32M | -$115.87M |
| EBITDA | -$21.16M | $26.59M | -$4.48M | -$99.03M | -$113.44M |
| EPS (diluted) | — | — | — | — | — |
| Weighted avg. shares (diluted) | 137.94M | 84.75M | 73.81M | 65.74M | 64.15M |
| Balance sheet | |||||
| Cash & equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M |
| Short-term investments | $124.39M | $62.57M | $157.34M | $0 | $99.70M |
| Receivables | $2.01M | $3.10M | $3.43M | $35.99M | $790,000 |
| Current assets | $143.92M | $107.31M | $182.94M | $237.10M | $310.30M |
| PP&E, net | $1.30M | $2.47M | $3.96M | $5.07M | $5.96M |
| Goodwill | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 |
| Total assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M |
| Current liabilities | $46.62M | $85.77M | $155.91M | $152.61M | $77.87M |
| Total liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $339.87M |
| Shareholders' equity | $99.01M | -$456,000 | -$47.45M | -$85.75M | -$459,000 |
| Shares outstanding | 170.19M | 80.10M | 67.31M | 66.23M | 65.39M |
| Cash flow statement | |||||
| Operating cash flow | -$75.59M | -$86.23M | -$56.03M | -$110.79M | -$119.03M |
| Capital expenditure | $220,000 | $310,000 | $840,000 | $1.74M | $1.61M |
| Free cash flow | -$75.81M | -$86.54M | -$56.88M | -$112.53M | -$120.64M |
| Investing cash flow | -$59.74M | $99.70M | -$150.67M | $98.26M | $22.49M |
| Financing cash flow | $110.45M | $7.52M | $30.23M | $648,000 | $110.21M |
| Depreciation & amortization | $1.20M | $1.60M | $2.00M | $2.30M | $2.60M |
| Stock-based compensation | $6.30M | $7.67M | $8.56M | $13.12M | $13.17M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.